Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
Mark Kris, MD, discusses the use of a checkpoint inhibitor and chemotherapy as neoadjuvant therapy for every patient with stage II and III lung cancer at the time of diagnosis.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2024 Category: Pharmaceuticals Source Type: news
A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
(MedPage Today) -- Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 3, 2024 Category: Hematology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer
New research shows that ctDNA clearance following neoadjuvant treatment of muscle-invasive urothelial cancer can help predict response to therapy and the risk for relapse.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 30, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable locally advanced esophageal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 22, 2024 Category: Hematology Source Type: news
Standard Therapy Beats Out Primary Surgery in Rectal Cancer Standard Therapy Beats Out Primary Surgery in Rectal Cancer
In locally advanced rectal cancer, primary surgery followed by selective adjuvant chemoradiation was inferior to standard neoadjuvant preoperative chemoradiation followed by surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Multiparametric MRI helps predict breast cancer treatment outcomes
Multiparametric MRI helps predict breast cancer treatment response, according to a report on the RSNA's Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge published January 5 in Radiology: Imaging Cancer.
The findings suggest that MRI could offer an effective way to tailor the care of women with the disease, wrote a team led by Wen Li, PhD, of the University of California, San Francisco.
"Outcomes of the BMMR2 challenge provide further compelling evidence of the value of functional breast MRI as an early marker of treatment response that may aid in critical escalation and de-...
Source: AuntMinnie.com Headlines - January 8, 2024 Category: Radiology Authors: Kate Madden Yee Tags: MRI Womens Imaging Breast Imaging Source Type: news
PET/CT predicts brain tumors in melanoma patients
PET/CT scans have the potential to predict brain metastasis in melanoma patients, according to a study published December 26 in Cancers.
In a retrospective study, a team at the University Hospital Salzburg in Austria studied baseline F-18 FDG-PET/CT imaging parameters in patients with melanoma and found they were associated with the development of metastatic brain tumors.
“In melanoma patients, identification of those who are at higher risk of brain metastasis occurrence can be crucial as subsequent surveillance and even prophylactic treatment options can be provided,” wrote lead author and nuclear medicine physician...
Source: AuntMinnie.com Headlines - January 3, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Molecular Imaging Nuclear Radiology Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
RSI predicts early response to chemotherapy in breast cancer
Restriction spectrum imaging (RSI) is a suitable method for evaluating neoadjuvant therapy response early for breast cancer, suggest findings presented December 6 at the San Antonio Breast Cancer Symposium.
In her presentation, Maren Andreassen, MD, PhD, from the University of California, San Diego discussed her team’s work, which found that a novel RSI cancer tissue classifier predicted response to neoadjuvant therapy after three weeks. The team also found that RSI could identify most cases with residual tumor at surgery.
“RSI performance was similar to performance by standard MRI by manual tumor measurement on dyna...
Source: AuntMinnie.com Headlines - December 8, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties MRI Breast Breast Imaging Source Type: news
Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy significantly increased the rate of pathologic complete response (pCR) and reduced residual cancer burden (RCB) in high-risk early-stage hormone receptor... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 7, 2023 Category: OBGYN Source Type: news
